We have talked too much about glucose deprivation.BUT this section is very important.
If we are interested in metabolic treatment(deprivation of cancer energy),targeting mitochondria is must.
A little long article but we can learn lots of things from it.I highly recommend friends to read.
It also talks about some drugs which we talked before like salinomycin,pyrvinium pamoate as OXPHOS inhibitors.
These results suggest that the dual blockade of glycolysis and mitochondrial respiration may represent a better way to eradicate CSC heterogeneity than focusing exclusively on glycolysis inhibition or suppression of mitochondrial respiration. Indeed, combined inhibition of glycolysis and mitochondrial respiration has been shown to be effective in suppressing tumour growth and metastasis.
Therefore, therapeutic strategies should focus on both targets, glycolysis and mitochondrial OXPHOS. Even though some studies reported that mitochondrial OXPHOS is also one of 3-BP targets, 3-BP has been mainly demonstrated to be the most potent glycolytic inhibitor among various types of inhibitors. However, including our studies, the results of in vivo studies that have used human HCC cell lines did not exhibit complete remission, but showed only partial remission after 3-BP treatment[18,19,43-70]. One reason why 3-BP did not completely suppress tumor growth might be the low efficiency to suppress mitochondrial OXPHOS, the lactate shuttle, and high redox potential in cancer cells. To overcome the weakness of glycolytic inhibitors, the inhibitors to target mitochondrial OXPHOS and other involved mechanisms such as the suppression of ROS production, might be effective when used simultaneously with glycolytic inhibitors as a combination treatment.
I agree and mentioned this point often in my post or comments including in this post https://www.cancertreatmentsresearch.com/glucose-absorption-inhibitors-to-inhibit-tumor-growth/